{
    "clinical_study": {
        "@rank": "61922", 
        "acronym": "RDPAC", 
        "arm_group": [
            {
                "arm_group_label": "Low dose - Wild genotype (LW)", 
                "description": "75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype"
            }, 
            {
                "arm_group_label": "Low dose - Variant genotype (LV)", 
                "description": "75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype"
            }, 
            {
                "arm_group_label": "High dose - Wild genotype (HW)", 
                "description": "300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype"
            }, 
            {
                "arm_group_label": "High dose - Variant genotype (HV)", 
                "description": "300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a prospective, observational study to estimate the relationship between dosage\n      of clopidogrel and platelet aggregation in Chinese with different genotype. The\n      investigators suppose both pretreatment dosage of clopidogrel before  percutaneous coronary\n      intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as\n      clinical outcome."
        }, 
        "brief_title": "Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype", 
        "condition": "Coronary Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  accept PCI in Chinese CHD patients\n\n          -  expected dual antiplatelet therapy (DAPT) at least 6 months\n\n        Exclusion Criteria:\n\n          -  another planned PCI within 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Chinese coronary heart disease (CHD) patient"
            }
        }, 
        "enrollment": {
            "#text": "880", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710436", 
            "org_study_id": "RDPAC2012"
        }, 
        "intervention_browse": {
            "mesh_term": "Clopidogrel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100037"
                }, 
                "name": "Cardiovascular Institute and Fu Wai Hospital, CAMS & PUMC"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "4", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in platelet aggregation", 
            "safety_issue": "No", 
            "time_frame": "1 month and 6 months after PCI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710436"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cardiovascular Institute & Fuwai Hospital", 
            "investigator_full_name": "Xiaoxing Zhang", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Major adverse cardiovascular events (MACE); Bleeding events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months after PCI"
        }, 
        "source": "Cardiovascular Institute & Fuwai Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiovascular Institute & Fuwai Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}